deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03617328

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (Mel-65)

Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Sponsor: Celldex Therapeutics

Conditions Melanoma
Interventions 6MHP CDX-1127 Montanide ISA-51 polyICLC
Updated 19 times since 2018 Last updated: Feb 2, 2024 Started: Nov 13, 2018 Primary completion: Jan 19, 2024 Completion: Jan 19, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Melanoma and is currently completed. Celldex Therapeutics leads this study, which shows 19 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Jul 2019 · 7 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~May 2020 · 6 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Dec 2020 · 3 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2022 · 13 months · monthly snapshot~May 2022 – ~May 2023 · 12 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Mar 2024 · 9 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 21 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  4. Jun 2023 — Mar 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 14 earlier versions

  1. May 2022 — May 2023 [monthly]

    Recruiting PHASE1_PHASE2

  2. Apr 2021 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  3. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Active Not Recruiting → Recruiting

  7. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Jun 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Active Not Recruiting → Recruiting

  9. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  10. Nov 2019 — May 2020 [monthly]

    Recruiting PHASE1_PHASE2

  11. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Suspended → Recruiting

  12. Jul 2019 — Sep 2019 [monthly]

    Suspended PHASE1_PHASE2

    Status: Recruiting → Suspended

  13. Dec 2018 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  14. Sep 2018 — Dec 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celldex Therapeutics
  • Craig L Slingluff, Jr
Data source: University of Virginia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations